News

Welcome to our growth capital news hub, spotlighting updates on our business and the innovative companies we partner with, driving success through strategic investments and collaboration.

GIP Backs Fido to Boost Ghana’s Financial Inclusion

GIP Ghana LTD invests in Fido Micro Credit LTD to boost financial inclusion, supporting Ghanaian SMEs and underserved populations with innovative digital loans.

Latest News

Partner Companies /
2 Dec 2024

Rikair Partners with GIP to Make Medical Grade Oxygen Accessible to Ghanaians

GIP Ghana Ltd invests in Rikair Company Limited to boost medical oxygen access nationwide, enhancing healthcare infrastructure and supporting Ghana’s SME growth.
Partner Companies /
28 Oct 2024

GIP Invests in Truecoco to Support Sustainable Agricultural Growth, Industrial Carbon Removal, and Local Community Development

GIP Ghana LTD invests in Truecoco Ghana Limited to expand soybean processing and launch a biochar carbon capture project, boosting sustainability and local economic growth.
Partner Companies /
23 Jan 2024

BII platform Growth Investment Partners Ghana makes its first investment to support eSAL’s expansion in Ghana

GIP Ghana launched by BII invests in eSAL boosting Ghanaian BPO growth infrastructure and jobs for 8,000 professionals.

Excluded Activities are:

  1. the mining or extracting of precious metals and other geological materials (but excluding services to companies engaged in such activities);
  2. the production of, or trade in:
    • hazardous chemicals, pharmaceuticals, pesticides and wastes, as specified in the 2004 Stockholm Convention on Persistent Organic Pollutants; the 2004 Rotterdam Convention on the Prior Informed Consent Procedure for Certain Hazardous Chemicals and Pesticides in International Trade; the 1992 Basel Convention on the Control of Transboundary Movements of Hazardous Wastes and their Disposal and WHO Recommended Classification of Pesticides by Hazard Class 1a (extremely hazardous); or 1b (highly hazardous);
    • ozone depleting substances, as specified in the 1999 Montreal Protocol on Substances that Deplete the Ozone Layer;
    • endangered or protected wildlife or wildlife products, as specified in the 1975 Convention on International Trade in Endangered Species or Wild Flora and Fauna;
    • any other product or activity deemed illegal under applicable local or national laws or regulations or subject to internationally agreed phase-outs or bans as defined in global conventions and agreements;
    • arms (i.e. weapons, munitions or nuclear products, primarily designated for military purposes); or
    • radioactive materials (excluding medical equipment, quality control (measurement) equipment, civilian power generation and any equipment in which the radioactive source could reasonably be considered to be trivial or adequately shielded);
  3. the production of, use of, or trade in unbonded asbestos fibres;
  4. unsustainable fishing methods such as blast fishing and drift net fishing in the marine environment using nets in excess of 2.5 kilometres in length;
  5. prostitution; and
  6. any of the following, to the extent that the activities represent more than 10% of the Group’s underlying portfolio volumes:
    • gambling, gaming casinos and equivalent enterprises;
    • tobacco or tobacco related products (except where the Group proposes to cease such activities completely within a period agreed with BII); or
    • pornography.
  7. speculative and/or unregulated use of cryptocurrencies;
  8. AI where it poses “unacceptable risk” as defined in the EU AI Act 2021;
  9. social media targeting children and other vulnerable people, and dating apps;
  10. products and services primarily designed for national security and intelligence services (e.g., NSO Group) where there is a reasonable risk of human rights abuses;
  11. any business if alcoholic beverages (except beer and wine) represent a substantial portion of such business;
  12. animal and human cloning, or;
  13. prisons and detention centres;
  14. any healthcare facility dedicated to high end cosmetic procedures and/or surgeries; and any private multi-specialty hospital that does not satisfy at least one of the Hospital Investment Criteria.
  15. Any educational institution or facility where companies are primarily involved in private, fee-charging schools that provide education from kindergarten (or equivalent) to the final year prior to tertiary level education, or companies that primarily provide educational services to private, fee-charging schools such that they resemble private fee-charging schools (“Barred K-12 Activity”).
The “Hospital Investment Criteria” shall be deemed satisfied if, at the date of the investment, the private multi-specialty hospital either significantly serves or demonstrates an intention to serve: (i) patients in the target segment of government payor public schemes; or (ii) patients living on US$ 8.00 or less per day. Investments in single specialty hospitals, and primary and secondary care chains are not subject to the Hospital Investment Criteria. ‘Primarily’ for purposes of 15 above ‎is defined as where (i) for companies, more than 10% of its consolidated balance sheet or earnings, or (ii) for financial institutions, more than 10% of its portfolio volumes, comes from a Barred K-12 Activity.